1
|
Wang Y, Otte A, Park H, Park K. In vitro-in vivo correlation (IVIVC) development for long-acting injectable drug products based on poly(lactide-co-glycolide). J Control Release 2025; 377:186-196. [PMID: 39542257 DOI: 10.1016/j.jconrel.2024.11.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2024] [Revised: 10/17/2024] [Accepted: 11/09/2024] [Indexed: 11/17/2024]
Abstract
In vitro-in vivo correlation (IVIVC), linking in vitro drug release to in vivo drug release or in vivo drug absorption, has been explored chiefly for oral extended-release dosage forms. Currently, there are no official guidelines on IVIVC development for non-oral drug delivery systems. Recently, many long-acting injectable (LAI) formulations based on poly(lactide-co-glycolide) (PLGA) have been developed to deliver various drugs, ranging from small molecules to peptides and proteins, for up to 6 months. The circumstances involved in the LAI formulations are drastically different from those in oral formulations, which generally deliver drugs for a maximum of 24 h. This article examines 37 IVIVC studies of PLGA microparticle formulations available in the literature. Understanding and establishing an IVIVC of LAI formulations requires more than merely plotting the percentage in vitro drug release against the percentage in vivo absorption. In vivo drug absorption (or release) should be measured to provide a complete pharmacokinetic profile when feasible. Accelerated in vitro release methods need to be respective of the real-time measurements by sharing the same release mechanism. Obtaining meaningful IVIVCs with predictive capability will be highly useful for future regulatory actions and for developing generic and new formulations.
Collapse
Affiliation(s)
- Yan Wang
- Food and Drug Administration, Center for Drug Evaluation and Research, Office of Generic Drugs, Office of Research and Standards, Silver Spring, MD 20993, USA
| | - Andrew Otte
- Purdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, USA
| | | | - Kinam Park
- Purdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, USA; Purdue University, Department of Industrial and Molecular Pharmaceutics, West Lafayette, IN 47907, USA.
| |
Collapse
|
2
|
Zheng Y, Wang Y, Sheng F, Wang S, Zhou Y, Li X, Li N, Song W, Song Z. Treatment of chronic osteomyelitis with gradient release of DGEA and vancomycin hydrogel-microsphere system and its mechanism. Front Pharmacol 2024; 15:1499742. [PMID: 39588147 PMCID: PMC11586164 DOI: 10.3389/fphar.2024.1499742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2024] [Accepted: 10/24/2024] [Indexed: 11/27/2024] Open
Abstract
In recent years, the treatment of chronic osteomyelitis mediated by biodegradable polymer platforms has received increasing attention. This paper reports an advanced drug delivery system, vancomycin (VA) and DGEA loaded microspheres embedded in injectable thermosensitive polypeptide hydrogels (i.e., hydrogel-microsphere (Gel-MP) construct), for continuous release of drugs with different mechanisms and more comprehensive treatment of chronic osteomyelitis. The Gel-MP construct exhibits continuous biodegradability and excellent biocompatibility. Microspheres (MP) are wrapped inside Gel. With the degradation of Gel, VA and MP are released from them, VA released with faster degradation speed, achieving a potent antibacterial effect and effectively controlling infection. Due to the slower degradation rate of MP compared to Gel, subsequently, DGEA is released from MP to induce bone formation and produce the effect of filling bone defects. Compared with other formulations, the in vivo combinational treatment of Gel/VA-MP/DGEA can simultaneously balance antibacterial and osteogenic effects. More importantly, local sustained-release drug delivery systems can significantly mitigate the systemic toxicity of drugs. Therefore, the injection local sequential drug delivery system has broad prospects in the clinical application of treating chronic osteomyelitis.
Collapse
Affiliation(s)
- Yuhao Zheng
- Department of Sports Medicine, Orthopedics’ Clinic, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Yue Wang
- Department of Sports Medicine, Orthopedics’ Clinic, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Fan Sheng
- Department of Dermatology, The Second Hospital of Jilin University, Changchun, Jilin, China
| | - Shu Wang
- Department of Radiotherapy, The Second Hospital of Jilin University, Changchun, Jilin, China
| | - Ying Zhou
- Department of Dermatology, The Second Hospital of Jilin University, Changchun, Jilin, China
| | - Xiaoxu Li
- Department of Sports Medicine, Orthopedics’ Clinic, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Ning Li
- Department of Sports Medicine, Orthopedics’ Clinic, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Wenling Song
- Department of Obstetrics, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Zhiming Song
- Department of Sports Medicine, Orthopedics’ Clinic, The First Hospital of Jilin University, Changchun, Jilin, China
| |
Collapse
|
3
|
Alkhalidi HM, Alahmadi AA, Rizg WY, Yahya EB, H P S AK, Mushtaq RY, Badr MY, Safhi AY, Hosny KM. Revolutionizing Cancer Treatment: Biopolymer-Based Aerogels as Smart Platforms for Targeted Drug Delivery. Macromol Rapid Commun 2024; 45:e2300687. [PMID: 38430068 DOI: 10.1002/marc.202300687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Revised: 02/15/2024] [Indexed: 03/03/2024]
Abstract
Cancer stands as a leading cause of global mortality, with chemotherapy being a pivotal treatment approach, either alone or in conjunction with other therapies. The primary goal of these therapies is to inhibit the growth of cancer cells specifically, while minimizing harm to healthy dividing cells. Conventional treatments, often causing patient discomfort due to side effects, have led researchers to explore innovative, targeted cancer cell therapies. Thus, biopolymer-based aerogels emerge as innovative platforms, showcasing unique properties that respond intelligently to diverse stimuli. This responsiveness enables precise control over the release of anticancer drugs, enhancing therapeutic outcomes. The significance of these aerogels lies in their ability to offer targeted drug delivery with increased efficacy, biocompatibility, and a high drug payload. In this comprehensive review, the author discuss the role of biopolymer-based aerogels as an emerging functionalized platforms in anticancer drug delivery. The review addresses the unique properties of biopolymer-based aerogels showing their smart behavior in responding to different stimuli including temperature, pH, magnetic and redox potential to control anticancer drug release. Finally, the review discusses the application of different biopolymer-based aerogel in delivering different anticancer drugs and also discusses the potential of these platforms in gene delivery applications.
Collapse
Affiliation(s)
- Hala M Alkhalidi
- Department of Clinical Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Jeddah, 21589, Saudi Arabia
| | - Amerh Aiad Alahmadi
- Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, 21589, Saudi Arabia
| | - Waleed Y Rizg
- Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, 21589, Saudi Arabia
- Center of Innovation in Personalized Medicine, 3D Bioprinting Unit, King Abdulaziz University, Jeddah, 21589, Saudi Arabia
| | - Esam Bashir Yahya
- Bioprocess Technology Division, School of Industrial Technology, Universiti Sains Malaysia, Penang, 11800, Malaysia
- Green Biopolymer, Coatings and Packaging Cluster, School of Industrial Technology, Universiti Sains Malaysia, Penang, 11800, Malaysia
| | - Abdul Khalil H P S
- Green Biopolymer, Coatings and Packaging Cluster, School of Industrial Technology, Universiti Sains Malaysia, Penang, 11800, Malaysia
- Bioresource Technology Division, School of Industrial Technology, Universiti Sains Malaysia, Penang, 11800, Malaysia
| | - Rayan Y Mushtaq
- Department of Pharmaceutics, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, 31441, Saudi Arabia
| | - Moutaz Y Badr
- Department of Pharmaceutical Sciences, College of Pharmacy, Umm Al-Qura University, Makkah, 24381, Saudi Arabia
| | - Awaji Y Safhi
- Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, 45142, Saudi Arabia
| | - Khaled M Hosny
- Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, 21589, Saudi Arabia
| |
Collapse
|
4
|
Kotla NG, Pandey A, Vijaya Kumar Y, Ramazani F, Fisch A. Polyester-based long acting injectables: Advancements in molecular dynamics simulation and technological insights. Drug Discov Today 2023; 28:103463. [PMID: 36481584 DOI: 10.1016/j.drudis.2022.103463] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2022] [Revised: 11/21/2022] [Accepted: 11/30/2022] [Indexed: 12/12/2022]
Abstract
Long-acting injectable (LAI) delivery technologies have enabled the development of several pharmaceutical products that improve patient health by delivering therapeutics from weeks to months. Over the last decade, due to its good biocompatibility, formulation tunability, wide range of degradation rates, and extensive clinical studies, polyester-based LAI technologies including poly(lactic-co-glycolic acid) (PLGA) have made substantial progress. Herein, we discuss PLGA properties with seminal approaches in the development of LAIs, the role of molecular dynamic simulations of polymer-drug interactions, and their effects on quality attributes. We also outline the landscape of various advanced PLGA-based and a few non-PLGA LAI technologies; their design, delivery, and challenges from laboratory scale to preclinical and clinical use; and commercial products incorporating the importance of end-user preferences.
Collapse
Affiliation(s)
- Niranjan G Kotla
- Novartis Institutes for Biomedical Research (NIBR), Novartis Pharma AG, Basel 4002, Switzerland.
| | - Abhijeet Pandey
- Technical Research and Development, Novartis Pharma AG, Hyderabad 500081, India.
| | - Y Vijaya Kumar
- Technical Research and Development, Novartis Pharma AG, Hyderabad 500081, India
| | - Farshad Ramazani
- Technical Research and Development (TRD), Novartis Pharma AG, Basel 4002, Switzerland
| | - Andreas Fisch
- Technical Research and Development (TRD), Novartis Pharma AG, Basel 4002, Switzerland
| |
Collapse
|
5
|
Lim YW, Tan WS, Ho KL, Mariatulqabtiah AR, Abu Kasim NH, Abd. Rahman N, Wong TW, Chee CF. Challenges and Complications of Poly(lactic- co-glycolic acid)-Based Long-Acting Drug Product Development. Pharmaceutics 2022; 14:614. [PMID: 35335988 PMCID: PMC8955085 DOI: 10.3390/pharmaceutics14030614] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Accepted: 02/19/2022] [Indexed: 12/13/2022] Open
Abstract
Poly(lactic-co-glycolic acid) (PLGA) is one of the preferred polymeric inactive ingredients for long-acting parenteral drug products that are constituted of complex formulations. Despite over 30 years of use, there are still many challenges faced by researchers in formulation-related aspects pertaining to drug loading and release. Until now, PLGA-based complex generic drug products have not been successfully developed. The complexity in developing these generic drug products is not just due to their complex formulation, but also to the manufacturing process of the listed reference drugs that involve PLGA. The composition and product attributes of commercial PLGA formulations vary with the drugs and their intended applications. The lack of standard compendial methods for in vitro release studies hinders generic pharmaceutical companies in their efforts to develop PLGA-based complex generic drug products. In this review, we discuss the challenges faced in developing PLGA-based long-acting injectable/implantable (LAI) drug products; hurdles that are associated with drug loading and release that are dictated by the physicochemical properties of PLGA and product manufacturing processes. Approaches to overcome these challenges and hurdles are highlighted specifically with respect to drug encapsulation and release.
Collapse
Affiliation(s)
- Yi Wen Lim
- Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang 43400, Malaysia; (Y.W.L.); (W.S.T.)
| | - Wen Siang Tan
- Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang 43400, Malaysia; (Y.W.L.); (W.S.T.)
- Laboratory of Vaccines and Biomolecules, Institute of Bioscience, Universiti Putra Malaysia, Serdang 43400, Malaysia;
| | - Kok Lian Ho
- Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Malaysia;
| | - Abdul Razak Mariatulqabtiah
- Laboratory of Vaccines and Biomolecules, Institute of Bioscience, Universiti Putra Malaysia, Serdang 43400, Malaysia;
- Department of Cell and Molecular Biology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang 43400, Malaysia
| | - Noor Hayaty Abu Kasim
- Faculty of Dentistry, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia;
| | | | - Tin Wui Wong
- Non-Destructive Biomedical and Pharmaceutical Research Centre, Smart Manufacturing Research Institute, Universiti Teknologi MARA, Puncak Alam 42300, Malaysia
| | - Chin Fei Chee
- Nanotechnology and Catalysis Research Centre, Universiti Malaya, Kuala Lumpur 50603, Malaysia
| |
Collapse
|